DOAC underdosing linked to increased risks in non-valvular AF patients

Lire cet article en français

Off-label prescribing of lower-dose direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) is associated with a higher risk of mortality, stroke and myocardial infarction (MI) and may not actually reduce bleeding risks, researchers have reported. 

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.